Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Monash IVF GroupMNIVF 77 3-Year EBITDA Growth Rate is 14.90% as of Dec. 2025. GuruFocus rates MNIVF with a GF Score™ of 77/100 and a GF Value™ of $0.85. The stock has 7 warning signs investors should review. Among 167 Medical Diagnostics & Research companies, Monash IVF Group ranks better than 53.89% on this metric.
During the past 12 months, Monash IVF Group's average EBITDA Per Share Growth Rate was 167.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 14.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -8.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -8.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Monash IVF Group was 14.90% per year. The lowest was -39.60% per year. And the median was -5.60% per year.
Monash IVF Group (OTCPK:MNIVF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Monash IVF Group 3-Year EBITDA Growth Rate Related Terms
MNIVF vs TMO, DHR, IDXX: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Monash IVF Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monash IVF Group 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Monash IVF Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Monash IVF Group's 3-Year EBITDA Growth Rate falls into.
Monash IVF Group 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 14.90% mean?
Monash IVF Group (MNIVF) has a 3-Year EBITDA Growth Rate of 14.90% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Monash IVF Group and its competitors. According to the industry distribution chart, Monash IVF Group ranks #77 out of 167 companies in the Medical Diagnostics & Research industry, placing it in the top 46.1%.
Is Monash IVF Group's 3-Year EBITDA Growth Rate too high?
Monash IVF Group's current 3-Year EBITDA Growth Rate is 14.90%. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.10. Monash IVF Group's value of 14.90% is 34.2% above this industry median. Based on the distribution chart, Monash IVF Group ranks #77 out of 167 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Monash IVF Group has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Monash IVF Group's 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Monash IVF Group ranks #77 out of 167 companies for 3-Year EBITDA Growth Rate. This puts Monash IVF Group in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 11.10. Monash IVF Group's value of 14.90% is 34.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.10, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Monash IVF Group's current 3-Year EBITDA Growth Rate of 14.90% is 34.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Monash IVF Group and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monash IVF Group's current 3-Year EBITDA Growth Rate is 14.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monash IVF Group stock overvalued right now?
Monash IVF Group (MNIVF) has a current 3-Year EBITDA Growth Rate of 14.90%. The stock's GF Value™ is $0.85, compared to a current price of $0.40 — trading 52.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 14.90% and 34.2% above the Medical Diagnostics & Research industry median of 11.10. Monash IVF Group's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Monash IVF Group (MNIVF), the current 3-Year EBITDA Growth Rate is 14.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Monash IVF Group (MNIVF) Overvalued in 2026?
Based on GuruFocus' analysis, Monash IVF Group stock appears to be undervalued.
The current stock price of $0.40 is trading 52.9% below its estimated GF Value™ of $0.85.
Key valuation signals for MNIVF:
3-Year EBITDA Growth Rate: 14.90%
GF Value™: $0.85 vs. price of $0.40 (52.9% below fair value)
Industry Position: 34.2% above the Medical Diagnostics & Research median (#77 of 167)
No single metric tells the full story. See the MNIVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Monash IVF Group Ltd is a provider of fertility services, specializing in Assisted Reproductive Services (ARS) and genetic care across Australia and South East Asia. The Group operates two main segments: Australia IVF and Ultrasound, which offer ARS, ultrasound, and related women's health services, and International IVF, which provides assisted reproductive care in South East Asia. The majority of revenue is generated from the Australian segment through its brands such as Fertility Solutions, KL Fertility, Monash IVF, Repromed, and others.
77GF Score
Get the complete analysis for MNIVF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNIVF has been successfully added to your 
